Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways

British Journal of Dermatology

Volumn 176, Issue 2, 2017, Pages 387-394

  Fujimura, T ^a   Kambayashi, Y ^a   Furudate, S ^a   Kakizaki, A ^a   Hidaka, T ^a   Aiba, S ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MACROPHAGE; METASTATIC MELANOMA; PAGET SKIN DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SENTINEL LYMPH NODE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; LYMPH NODE METASTASIS; METABOLISM; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL CULTURE;

CHEMOKINE CCL17; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LANGERHANS CELLS; LYMPHATIC METASTASIS; NF-KAPPA B; PAGET DISEASE, EXTRAMAMMARY; RANK LIGAND; RECEPTOR CROSS-TALK; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 85007110531     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14864     Document Type: Article

References (25)

1. Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. J Clin Pathol 2000; 53:742–9.
2. Shiomi T, Noguchi T, Nakayama H et al. Clinicopathological study of invasive extramammary Paget's disease: subgroup comparison according to invasion depth. J Eur Acad Dermatol Venereol 2013; 27:589–92.
3. Ackerman AB, Kessler G, Gyorfi T et al. Contrary view: the breast is not an organ per se, but a distinctive region of skin and subcutaneous tissue. Am J Dermatopathol 2007; 29:211–18.
4. González-Suárez E. RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 2011; 13:222–8.
5. Kambayashi Y, Fujimura T, Furudate S et al. The possible interaction between receptor activator of nuclear factor kappa-B ligand (RANKL) expressed by extramammary Paget cells and its ligand on dermal macrophages. J Invest Dermatol 2015; 135:2547–50.
6. + M2 macrophages. J Invest Dermatol 2015; 135:2884–7.
7. Fujimura T, Kambayashi Y, Furudate S et al. Receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK signaling promotes cancer-related inflammation through M2 macrophages. Exp Dermatol 2016; 25:397–9.
8. Frankenberger C, Rabe D, Bainer R et al. Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of pro-metastatic tumor-associated macrophages. Cancer Res 2015; 75:4063–73.
9. + macrophages in invasive and non-invasive extramammary Paget's disease. Acta Derm Venereol 2012; 92:625–8.
10. Fujimura T, Furudate S, Kambayashi Y et al. Potential use of bisphosphonates in invasive extramammary Paget's disease: an immunohistochemical Investigation. Clin Dev Immunol 2013; 2013:164982.
11. Elder DE, Elemenitsas R, Johnson BL Jr et al. Lever's Histopathology of the Skin, 10th edn. Philadelphia, PA: Lippincott-Raven, 2008.
12. + hematopoietic progenitor cells into Langerhans cells under serum-free conditions without granulocyte-macrophage colony-stimulating factor. J Invest Dermatol 2003; 120:256–65.
13. Loser K, Mehling A, Loeser S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12:1372–9.
14. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390:175–9.
15. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186:2075–80.
16. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95:3597–602.
17. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412–24.
18. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315–23.
19. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337–42.
20. Kupas V, Weishaupt C, Siepmann D et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 2011; 131:944–55.
21. + regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. Gynecol Oncol 2011; 120:296–9.
22. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373–80.
23. Furudate S, Fujimura T, Kambayashi Y et al. Immunosuppressive and cytotoxic cells in invasive versus non-invasive Bowen's disease. Acta Derm Venereol 2014; 94:337–9.
24. + regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides. Br J Dermatol 2008; 158:1256–63.
25. Azim H, Azim HA Jr. Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther 2013; 13:195–201.